

***IN THE CLAIMS:***

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-46. Cancelled.

47. (New) An immunoglobulin-polypeptide chimera comprising an immunoglobulin having at least one CDR region, wherein at least one diabetogenic epitope is inserted within the at least one CDR region.
48. (New) The chimera of claim 47 wherein the epitope comprises a diabetogenic fragment of INS or GAD.
49. (New) The chimera of claim 48 wherein the epitope comprises INS $\beta$  or a diabetogenic fragment thereof.
50. (New) The chimera of claim 49 wherein the epitope comprises amino acid sequence of SEQ ID No: 1 or a diabetogenic fragment thereof.
51. (New) The chimera of claim 48 wherein the epitope comprises a diabetogenic fragment of GAD.
52. (New) The chimera of claim 51 wherein the epitope comprises amino acid sequence of SEQ ID No: 3 or a diabetogenic fragment thereof.
53. (New) The chimera of claim 51 wherein the epitope comprises amino acid sequence of SEQ ID No: 4 or a diabetogenic fragment thereof.
54. (New) The chimera of claim 47 wherein the chimera is capable of being endocytosed by Fc receptor cells and processed by said cells to present the at least one protein fragment or peptide to endogenous MHC Class II molecules, thereby reducing or preventing activation of T cells specific for the diabetogenic epitope.
55. (New) The chimera of claim 47 wherein the immunoglobulin comprises IgG.
56. (New) The chimera of claim 55 wherein said IgG is human IgG or humanized IgG.
57. (New) The chimera of claim 47, wherein the at least one CDR region is selected from the group consisting of CDR1, CDR2, or CDR3.

58. (New) The chimera of claim 47, wherein the at least one CDR region comprises CDR3.
59. (New) The chimera of claim 47, wherein the wherein at least one diabetogenic epitope replaces a D region within said at least one CDR region.
60. (New) The chimera of claim 47 wherein the chimera is soluble.
61. (New) A pharmaceutical composition comprising a chimera according to claim 1 and a pharmaceutically acceptable carrier.
62. (New) A method of treating or preventing type-1 diabetes in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition according to claim 61.
63. (New) The method of claim 62 wherein the subject is in pre-insulinitis stage of type-1 diabetes when treatment is initiated.
64. (New) The method of claim 62 wherein the subject has not yet undergone IAA seroconversion when treatment is initiated.
65. (New) The method of claim 62 wherein the subject has seroconverted and produces autoantibodies against one or more  $\beta$ -cell associated antigens when treatment is initiated.